"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
| Descriptor ID |
D007155
|
| MeSH Number(s) |
D27.505.696.477
|
| Concept/Terms |
Immunologic Factors- Immunologic Factors
- Immune Factors
- Factors, Immune
- Immunological Factors
- Factors, Immunological
- Factors, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".
Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".
This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 3 | 2 | 5 |
| 2006 | 7 | 1 | 8 |
| 2007 | 4 | 2 | 6 |
| 2008 | 5 | 3 | 8 |
| 2009 | 5 | 6 | 11 |
| 2010 | 8 | 0 | 8 |
| 2011 | 4 | 3 | 7 |
| 2012 | 5 | 4 | 9 |
| 2013 | 2 | 0 | 2 |
| 2014 | 5 | 3 | 8 |
| 2015 | 2 | 2 | 4 |
| 2016 | 4 | 4 | 8 |
| 2017 | 1 | 0 | 1 |
| 2018 | 6 | 1 | 7 |
| 2019 | 7 | 4 | 11 |
| 2020 | 3 | 5 | 8 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 6 | 6 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals. Front Immunol. 2024; 15:1348041.
-
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2023 Dec 30; 17(12):2012-2025.
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
-
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. J Thorac Oncol. 2024 02; 19(2):285-296.
-
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 12; 18(12):1731-1742.
-
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 05 04; 141(18):2194-2205.
-
Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Inflamm Bowel Dis. 2023 05 02; 29(5):695-704.
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
-
TLR3 agonist nanoscale coordination polymer synergizes with immune checkpoint blockade for immunotherapy of cancer. Biomaterials. 2022 11; 290:121831.
-
Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Ann Allergy Asthma Immunol. 2022 Dec; 129(6):758-768.e4.